Numerous strategies that target CD47 in solid and hematologic malignancies are in development (17–26), and preclinical evidence suggests that disrupting CD47 signaling promotes phagocytosis, inhibits tumor growth and survival, and enhances the antitumor activity of opsonizing therapeutic antibodies (9, 17). Here, CD47 is linked to hematologic disorder.